Evidence map›Paper›PMID 28841634›Full record

ArticleCurrent opinion in endocrinology, diabetes, and obesity2017

Mammalian target of rapamycin complex 1 and FoxO1 in the transcriptional control of lipolysis and de novo lipogenesis.

Konstantin V Kandror

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current opinion in endocrinology, diabetes, and obesity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Konstantin V KandrorDepartment of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, USA.
Boston University · US

Funding

INSULIN REGULATION OF CELL NUTRITIONR01DK052057 · NIDDK · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KANDROR, KONSTANTIN V · 1997 to 2023
$7.1M
Regulation of lipolysis by mTORC1R01DK107498 · NIDDK · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KANDROR, KONSTANTIN V · 2016 to 2019
$1.5M
Insulin regulation of cell nutritionR56DK052057 · NIDDK · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KANDROR, KONSTANTIN V · 2008 to 2014
$418k
NIDDK NIH HHS R01 DK052057NIDDK NIH HHS R01 DK107498NIDDK NIH HHS R56 DK052057
6 · The paper itself

Abstract

purpose of reviewPostprandial suppression of lipolysis in adipose tissue and stimulation of de novo lipogenesis (DNL) in the liver by insulin are essential for the metabolic homeostasis in the mammalian organism. The mechanism of coregulation of lipolysis and DNL is not clear. RECENT

findingsInsulin controls both lipolysis and DNL at the level of transcription via the same mammalian target of rapamycin complex 1 (mTORC1) and FoxO1-mediated signaling pathways. SUMMARY: mTORC1 suppresses lipolysis in adipose tissue and activates DNL in the liver, whereas FoxO1 has the opposite effect. Individual inputs of either mTORC1 or FoxO1 in the regulation of lipid metabolism may be difficult to evaluate because of the cross talk between these pathways.

Indexed as

Adipose TissueAnimalsForkhead Box Protein O1Gene Expression RegulationHumansInsulinInsulin ResistanceLipid MetabolismLipogenesisLipolysisLiverMechanistic Target of Rapamycin Complex 1Signal TransductionTranscription, GeneticForkhead Box Protein O1FOXO1 protein, humanInsulinMechanistic Target of Rapamycin Complex 1

Identifiers

PMID28841634
PMCPMC11210950
OpenAlexW2749064220

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.